Susquehanna Fundamental Investments, LLC Crispr Therapeutics Ag Transaction History

Susquehanna Fundamental Investments, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$60.67 - $89.12 $1.43 Million - $2.09 Million	23,503 New	23,503 $1.6 Billion
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $748,963 - $1.03 Million	-12,258 Reduced 38.39%	19,674 $1.29 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $538,282 - $801,908	10,120 Added 46.4%	31,932 $2 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $137,306 - $218,017	1,959 Added 9.87%	21,812 $1.65 Million
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $315,943 - $449,086	-2,867 Reduced 12.62%	19,853 $2.22 Million
Q2 2021 Aug 11, 2021	BUY	$100.84 - $161.89 $2.29 Million - $3.68 Million	22,720 New	22,720 $3.68 Million

488

59M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.1B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.